Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Lung Cancer. 2014 May 14;15(5):379–386. doi: 10.1016/j.cllc.2014.04.002

Table 3.

Time to pleurodesis and median overall survival by EGFR- and KRAS-mutation analysis.

Mutation status No. No. pleurodesis Median time to pleurodesis, d (range) Median OS, d (range)
EGFR-mutated 4 3 405.5 (14, 743) 291 (164, 787)
EGFR-wild type 16 13 31.5 (13, 142) 326 (62, 882)
KRAS-mutated 5 3 42 (15, 42) 343 (74, 789)
KRAS-wild type 11 10 22 (13, 743) 247 (62, 787)

No.= number; OS= overall survival, d= days.